- Home
- NRGV vs DSGN Comparison
NRGV vs DSGN Comparison
Compare NRGV & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRGV
- DSGN
- Stock Information
- Founded
- NRGV 2017
- DSGN 2017
- Country
- NRGV United States
- DSGN United States
- Employees
- NRGV N/A
- DSGN N/A
- Industry
- NRGV Industrial Machinery/Components
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- NRGV Miscellaneous
- DSGN Health Care
- Exchange
- NRGV Nasdaq
- DSGN Nasdaq
- Market Cap
- NRGV 190.1M
- DSGN 224.8M
- IPO Year
- NRGV N/A
- DSGN 2021
- Fundamental
- Price
- NRGV $0.92
- DSGN $4.01
- Analyst Decision
- NRGV Buy
- DSGN Hold
- Analyst Count
- NRGV 3
- DSGN 1
- Target Price
- NRGV $1.58
- DSGN $4.00
- AVG Volume (30 Days)
- NRGV 1.3M
- DSGN 94.1K
- Earning Date
- NRGV 05-12-2025
- DSGN 05-07-2025
- Dividend Yield
- NRGV N/A
- DSGN N/A
- EPS Growth
- NRGV N/A
- DSGN N/A
- EPS
- NRGV N/A
- DSGN N/A
- Revenue
- NRGV $46,974,000.00
- DSGN N/A
- Revenue This Year
- NRGV $392.18
- DSGN N/A
- Revenue Next Year
- NRGV $48.23
- DSGN N/A
- P/E Ratio
- NRGV N/A
- DSGN N/A
- Revenue Growth
- NRGV N/A
- DSGN N/A
- 52 Week Low
- NRGV $0.60
- DSGN $2.60
- 52 Week High
- NRGV $2.70
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- NRGV 53.38
- DSGN 54.38
- Support Level
- NRGV $0.80
- DSGN $3.67
- Resistance Level
- NRGV $1.00
- DSGN $4.20
- Average True Range (ATR)
- NRGV 0.10
- DSGN 0.32
- MACD
- NRGV -0.01
- DSGN 0.05
- Stochastic Oscillator
- NRGV 40.15
- DSGN 82.65
About NRGV Energy Vault Holdings Inc.
Energy Vault Holdings Inc is a grid-scale energy storage company that is driving a faster transition to renewable power by solving the intermittence issues that are inherent to the prevalent sources of renewable energy, solar and wind. Geographical presence in United States, China and Other. Majority of its revenue comes from U.S.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.